Evaluation of the effects of curcumin capsules on prevention and prognosis of chemotherapy and radiotherapy induced oral mucositis in patients with cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100101002950N6

Enrollment

Registered

2019-02-12

Start date

2019-03-06

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral mucositis induced by chemotherapy and radiotherapy. Oral mucositis (ulcerative) due to antineoplastic therapy

Interventions

Intervention 1: Intervention group: This group will take 80 mg Curcumin capsule produced by Exir Nano Sina company twice a day during 7 weeks since the onset of chemotherapy and radiotherapy. Interven

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients under head and neck radiotherapy Patients under chemotherapy

Exclusion criteria

Exclusion criteria: Patients with oral lesions Patients with systemic diseases Smoking

Design outcomes

Primary

Measure	Time frame
Oral mucositis. Timepoint: onset of treatment, first week, second week, fourth week and seventh week. Method of measurement: Severity of erythema and ulceration by WHO and amount of pain by NRS.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Seyed Javad Kia

Rasht University of Medical Sciences

Djavadkia@gums.ac.ir+98 13 3348 6406

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 14, 2026